Advancing patient care in neurodegenerative diseases with unmet medical needs
AstraZeneca is committed to discovering and developing compounds to improve patient care in neuroscience.
With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders.
Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers
Our focus on unmet medical needs
More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.
Opioid-induced constipation (OIC)
OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.
Alzheimer's disease (AD)
AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.
Opportunities for collaboration
What we're working on
We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.
Image: Artistic rendering of BACE enzyme.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Infection, Neuroscience and Gastrointestinal (as at 30 September 2015)
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.